Cost-Effectiveness of Dabigatran (150 mg Twice Daily) and Warfarin in Patients ≥ 65 Years with Non-Valvular Atrial Fibrillation

Dabigatran has been shown to be superior to warfarin for stroke prevention in non-valvular atrial fibrillation (NVAF) but with higher out-of-pocket costs for patients. Although dabigatran has been shown to be cost-effective from a societal perspective, cost implications for individual patients and insurers are not well-described. We aimed to assess cost perspectives of each payer (Medicare and patient) in relation to administration, monitoring and adverse outcomes for dabigatran and warfarin in patients with and without prescription drug coverage.
Source: The American Journal of Cardiology - Category: Cardiology Authors: Source Type: research